[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Shanghai Refreshgene Technology Co., Ltd.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":39},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":5},"100526954",false,"NCT06141460","Safety and Efficacy of RRG001 Gene Therapy in Subjects With Neovascular Age-related Macular Degeneration (nAMD)","A Phase I\u002FIIa, Dose-escalation and Dose-extension Study to Evaluate the Safety and Efficacy of Single Subretinal Injection of RRG001 in Subjects With Neovascular Age-related Macular Degeneration","Inclusion Criteria:\n\n* Subjects that are willing and able to follow study procedures.\n* Patinets ≥50 years old.\n* Clinically diagnosed with CNV secondary to nAMD.\n* BCVA of the study eye is ≥5 letters and ≤73 letters(Snellen 20\u002F800\\~20\u002F40), as well as that of the other eye ≥19 letters(Snellen 20\u002F400).\n* Responding to anti-VEGF\n\nExclusion Criteria:\n\n* Presence of any other eye diseases other than nAMD in study eye that would affect the treatment or confusing the interpretation of the study results , as judged by the investigator.\n* CNV or macular edema in the study eye secondary to any causes other than AMD.\n* Uncontrolled glaucoma.\n* Uncontrolled hypertension despite medication.\n* Pregnant or lactating women or individuals with reproductive potential who are unwilling to take effective contraception during the study period.","ALL","50 Years",{"count":18,"type":19},48,"ESTIMATED","INTERVENTIONAL",[22,23],"PHASE1","PHASE2","A Phase I\u002FIIa, Dose-escalation and Dose-expansion Study to Evaluate the Safety and Efficacy of Single Subretinal Injection of RRG001 in Subjects With Neovascular Age-related Macular Degeneration",[26],"Neovascular Age-related Macular Degeneration","RECRUITING","2024-11-12",{"date":30,"type":31},"2024-11-14","ACTUAL",{"date":33,"type":31},"2023-12-12",{"date":35,"type":19},"2030-12-31",{"name":37,"class":38},"Shanghai Refreshgene Technology Co., Ltd.","INDUSTRY",""]